Avidity Biosciences Inc (Avidity Biosciences) is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company product pipeline include AOC 1001, AOC 1044 and AOC 1020. Its pipeline treats myotonic dystrophy type 1 (DM1), duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity Biosciences carries out AOC components such as monoclonal, linker, siRNA and PMO. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
10578 Science Center Drive, Suite 125, San Diego, California, 92121
Website
www.aviditybiosciences.com
Telephone
1 858 4017900
No of Employees
253
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RNA (NASD)
Revenue (2022)
$9.6M
3.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-22%
(2022 vs 2021)
Market Cap*
$2.3B
Net Profit Margin (2023)
XYZ
-17.7%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| AOC 1001 - Myotonic Dystrophy Type 1 (DM1) |
| AOC 1044 - Duchenne Muscular Dystrophy (DMD) |
| AOC 1020- Facioscapulohumeral Muscular Dystrophy (FSHD) |
Competitor Comparison
| Key Parameters | Avidity Biosciences Inc | Capricor Therapeutics Inc | Halo-Bio RNAi Therapeutics Inc | Prothelia Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Beverly Hills | Seattle | Milford |
| State/Province | California | California | Washington | Massachusetts |
| No. of Employees | 253 | 74 | - | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Troy Wilson, Ph.D | Chairman | Executive Board | 2012 | 54 |
| Sarah Boyce | President; Chief Executive Officer; Director | Executive Board | 2019 | 51 |
| Michael MacLean | Chief Business Officer; Chief Financial Officer | Senior Management | 2022 | 57 |
| W. Michael Flanagan | Chief Scientific and Technical Officer | Senior Management | 2023 | 61 |
| Teresa McCarthy | Chief Human Resources Officer | Senior Management | 2020 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer